Kornimate/medical-research-clean huggingface dataset:
a real-world study of antiviral therapy in children with chronic hepatitis b

Conditions: HBV; Chronic Hepatitis b

Summary: this is a multicenter, prospective, real-world study. the study plans to include a total of 2000 patients who meet the inclusion and exclusion criteria, consisting of 1600 treatment-naive patients and 400 treatment-experienced patients. the effectiveness and safety of different treatment strategies will be evaluated in children aged 1-12 years with treatment-naive and treatment-experienced chronic hepatitis b (chb) and chronic hbv infection.


Eligibility criteria:
inclusion criteria: * initial treatment group: 1. the guardian understands and signs the informed consent form (both parents must sign), and adheres to the relevant requirements of this study. if the participant is 8 years old or older, they must also sign the informed consent form. for participants under 8 years old who can express consent, their consent must be clearly documented. 2. age: ≥1 year and \<13 years, either sex; 3. positive for hbsag and/or hbv dna for more than 6 months; 4. no prior antiviral treatment. * treated group: 1. the guardian understands and signs the informed consent form (both parents must sign), and adheres to the relevant requirements of this study. if the participant is 8 years old or older, they must also sign the informed consent form. for participants under 8 years old who can express consent, their consent must be clearly documented. 2. age: ≥3 years and \<13 years, either sex; 3. previously diagnosed with chronic hepatitis b and received antiviral treatment with nas for more than 1 year and currently on treatment; 4. no history of ifnα use in the past 6 months; 5. negative for hbv dna; 6. hbsag quantification \<10,000 iu/ml (hbsag can be negative in the drug discontinuation observation group); 7. the drug discontinuation observation group must also achieve negative hbv dna and hbeag seroconversion for at least 1 year (based on continuous results from three consecutive reviews), and hbsag \<10,000 iu/ml; nas will be discontinued after enrollment. exclusion criteria: * 1.in the interferon group, blood white blood cell count \ 34μmol/l, or serum albumin \ 133μmol/l; 2.coexistence of other active infections; 3. coexistence of other chronic liver diseases or active liver diseases, such as autoimmune liver disease, drug-induced liver injury, wilson's disease, decompensated cirrhosis, liver cancer; 4. coexistence of other severe systemic diseases or malignant tumors, etc.; 5. history of allergy to nucleoside analogues or interferon; 6. subjects whom the investigator deems to have poor compliance, unable or unwilling to provide informed consent, or unable to adhere to the study requirements, or other conditions not suitable for participation in this study.

Keywords: nucleos(t)ide analogues（nas） interferon alpha（ifnα）
impact of ai-supported teaching on clinical decision-making in nursing students

Conditions: Nursing Education Research

Summary: this clinical trial aims to explore whether an ai-supported teaching method can help nursing students improve their clinical decision-making skills and knowledge during case-based learning. the study focuses on third-year nursing students enrolled in an emergency care course. participants are divided into two groups: one group receives traditional case-based instruction, while the other uses chatgpt (an ai language model developed by openai- (chat generative pre-trained transformer)) to support their case-solving activities. all students complete a pretest and posttest to assess their knowledge and perceptions of clinical decision-making. the main goals are to find out whether the ai-supported group performs better than the traditional group and to evaluate the relationship between students' knowledge and their clinical decision-making scores. by comparing these two teaching methods, researchers aim to understand whether integrating ai tools into nursing education can enhance learning outcomes.


Eligibility criteria:
inclusion criteria: * successful completion of prerequisite courses (fundamentals of nursing i-ii, * medical-surgical diseases nursing, and pediatric nursing) along with associated clinical internships * enrollment in the emergency care course during the study period * volunteering to participate and providing written informed consent * must be a third-year undergraduate nursing student. * must be enrolled in the "emergency care nursing" course during the 2024-2025 spring semester. * must be attending the faculty of health sciences, department of nursing, at yeditepe university. * completion of all data collection forms exclusion criteria: * failure to complete prerequisite courses or required clinical internships * irregular attendance in the emergency care course * declining to participate or failure to provide written informed consent * submission of incomplete data collection forms

Keywords: clinical decision-making artificial intelligence case-based learning surgical nursing pediatric nursing
distress in crisis situations during covid-19

Conditions: Stress, Psychological

Summary: there are many scales for screening or assessing the impact of a disease. these scales are generally used to diagnose or assess the severity of a disease and are carried out at the request of a physician by the patient. conversational agents could make it possible to administer these questionnaires remotely, analyse them and use the results on a large scale, without prior medical intervention. the main objective of this study is to quantify and qualify the distress of a large population in times of pandemic crisis.

the peritraumatic distress inventory is the standard tool designed to assess distress in times of crisis. it consists of 13 questions. questions will be submitted to the participants from the vik chatbot. responses will be analysed and compared according to the demographics and pathologies encountered.

Eligibility criteria:
inclusion criteria: * age \> 18 years old * collection of the subject's non-opposition * patient registration on vik breast, vik asthma, vik migraine, vik depression exclusion criteria: * patient unable to formulate non-opposition
a phase 1b study of medi4736 in combination with tremelimumab in subjects with advanced non-small cell lung cancer

Conditions: NSCLC; Non-small Cell Lung Cancer; Lung Cancer

Summary: the purpose of this study is to determine if medi4736 will be adequately tolerated in combination with tremelimumab in subjects with advanced non-small cell lung cancer (nsclc).

this is a multicenter, open-label, dose-escalation, and dose expansion study of medi4736 in combination with tremelimumab to evaluate the safety, tolerability, pharmacokinetic (pk), immunogenicity, and antitumor activity of medi4736 in combination with tremelimumab in adult subjects with advanced nsclc.

Eligibility criteria:
inclusion criteria: 1. age ≥ 18 years 2. advanced non-small cell lung cancer 3. eastern cooperative oncology group (ecog) performance status of 0-1 4. adequate organ and marrow function exclusion criteria: 1. any concurrent chemotherapy, immunotherapy, biologic, or hormonal therapy for cancer treatment 2. current or prior use of immunosuppressive medication within 14 days before the first dose of study drugs 3. active or prior documented autoimmune disease within the last 2 years.

Keywords: anti-ctla-4 anti-pd-l1 immunotherapy imtc
bioequivalence study of torrent pharmaceutical limited's isosorbide mononitrate 120 mg er tablets under fed conditions

Conditions: Healthy

Summary: objective: to compare the single dose bioavailability of torrent's isosorbide mononitrate 120 mg er tablets (test) and isosorbide mononitrate 120 mg er tablets (reference) of kremers urban, usa under fed condition. dosing periods were separated by a washout period of 8 days. study design: randomized, two-way crossover, single-dose, open-label study in healthy human adult subjects


Eligibility criteria:
inclusion criteria: * healthy males within the age range of 18 to 55 years. * a body mass index within 18-25 kg/m2. * given written informed consent to participate in the study. * absence of diseases markers of hiv 1 \& 2, hepatitis b \& c virus and rpr. * absence of significant disease or clinically significant abnormal laboratory values on laboratory evaluation, medical history and physical examination during the screening. * a normal 12-lead ecg. * a normal chest x-ray. * comprehension of the nature and purpose of the study and compliance with the requirements of the entire protocol. * no history or no evidence of hypersensitivity or idiosyncratic reactions to other nitrates or nitrites. * no history of allergic rash. * no history of significant systemic diseases. * no history of psychiatric disorders or addiction to any recreational drug or drug dependence. * no donation of blood within 56 days prior to study check-in. * no participation in any clinical study within the past 56 days. * no receipt of any prescription drugs or otc products, with in two weeks prior to study check-in. * no history of dehydration from diarrhea, vomiting or any other reason within a period of 24 hours prior to study check-in. * no family history of neurological disorders. * not consumed alcohol and xanthine containing food and beverages, cigarettes and tobacco products, for at-list 48 hours, prior to study check-in. * negative results for drugs of abuse in urine and alcohol breath analysis during check-in of each period. * not consumed grape fruit juice within the 48 hours prior to study check-in. exclusion criteria: * blood pressure systolic\> 140 mm hg and \ 90 mm hg * history of seizures * history of alcohol consumption for more than 2 units/day. * high caffeine or tobacco consumption * history of difficulty with donating blood or difficulty in accessibility of veins. * any unusual or abnormal diet, for whatever reason e.g. fasting due to religious reasons. * used any pharmacological agents known to significantly induce or inhibit drug metabolizing enzymes within 14 days of the start of the study
the leukotriene receptor antagonist montelukast in the treatment of non-alcoholic steatohepatitis

Conditions: Steatohepatitis, Nonalcoholic

Summary: the aim of the current study is to evaluate the safety and efficay of montelukast in treatment of patients with fatty liver disease.


Eligibility criteria:
inclusion criteria: - the inclusion criteria were adult patients (age \>18 years old) of both sexes, overweight/obese subjects with presence of evidence of hepatic steatosis by imaging (increased liver echogenicity, stronger echoes in the hepatic parenchyma, vessel blurring, and narrowing of the lumen of the hepatic veins). patients with mild to moderate elevation in aminotransferase activities (\> 2 but \ 36, fibro-scan score \>7 kpa and \<12.5 kpa (f0-f3), and hair score of 2 or 3 were included in the study. exclusion criteria: - the exclusion criteria included smokers, patients with secondary hepatic fat accumulation which results from using steatogenic medications or hereditary disorders. alcohol consumers, patients with wilson's disease, hemochromatosis, viral hepatitis, decompensated liver disease, inflammatory diseases, diabetes, depression and patients with other comorbid conditions that elevate transaminases (congestive heart failure and malignancy) pregnancy and lactating women were excluded
intrathecal enzyme replacement for hurler syndrome

Conditions: Hurler Syndrome

Summary: this protocol will examine whether the enzyme alpha-l-iduronidase (laronidase), delivered into the spinal fluid of patients with hurler syndrome at intervals before and after bone marrow transplant, is a safe and effective approach to slow the neurologic degeneration seen in hurler patients undergoing transplantation.

subjects will receive an infusion of laronidase into his/her spinal fluid approximately 12 weeks before, 2 weeks before, 100 days after and 6 months after transplant. this procedure is done by lumbar puncture (also called a "spinal tap").

Eligibility criteria:
inclusion criteria: * patients with a diagnosis of mps ih (hurler syndrome) are candidates for this protocol if they are being considered for hematopoietic stem cell transplantation according the university of minnesota guidelines. exclusion criteria: * patients are less than 6 months old, or older than 3 years of age. * there is a history of clinically-severe hypersensitivity to laronidase. * there is a contraindication for repeated lumbar puncture. * the family is not willing to undergo the necessary procedures and evaluations inherent in the study. * consent has not been signed for participation in the 2004-09 study of intravenous laronidase administration.

Keywords: hurler syndrome mucopolysaccharidosis type i iduronidase deficiency
diagnostic value of d-dimer/fibrinogen ratio in patients with acute aortic dissection

Conditions: Aortic Dissection; Pulmonary Embolism

Summary: acute aortic dissection is rare but potentially life-threatening disease with an incidence of 5-30 cases per million, annually. therefore prompt diagnosis is crucial. d-dimer values have been shown to be useful in the diagnosis of acute aortic dissection. fibrinogen levels have been shown to be low, normal or high in individuals with acute aortic dissection. this study aims to investigate whether d-dimer/fibrinogen ratio can be valuable for diagnosis of acute aortic dissection.


Eligibility criteria:
inclusion criteria: * diagnosis of acute aortic dissection * diagnosis of acute pulmonary embolism * diagnosis of non-cardiac chest pain exclusion criteria: * any etiology of chest pain other than acute aortic dissection, acute pulmonary embolism, or non-cardiac chest pain * participants who do not give consent for enrollment
framingham cycle v offspring-spouse nutrition studies

Conditions: Cardiovascular Diseases; Coronary Disease; Heart Diseases; Hypertension; Obesity; Diabetes Mellitus; Atherosclerosis

Summary: to examine the associations between diet, nutrition and coronary heart disease (chd) incidence over seven years using the cycle v framingham offspring/spouse examination ; to examine the cross-sectional associations between dietary variables and major cardiovascular disease risk factors, to examine changes in dietary behaviors and their determinants over seven years; and to characterize the influences of dietary behavior changes on risk factor status between 1984-88 and 1991-94.

design narrative: the data collection efforts and cross-sectional analyses were carried out among approximately 3800 males and females during the scheduled 1991-1994 cycle v framingham offspring/spouse study. the secular trend and longitudinal analyses also included data that were collected during the cycle iii offspring/spouse studies in 1984-88. of particular interest were dietary variables which play a major role in serum total cholesterol and lipoprotein regulation. additional dietary variables which were associated with major cardiovascular risk factors ((elevated) blood pressure, glucose (in)tolerance, (excess) body weight or physical (in)activity, and smoking) or that may predict chd endpoints were included in the analyses. the potential confounding effects or interactions between dietary and risk factor variables were considered. separate analyses were carried out in males and females. the study completion date listed in this record was obtained from the "end date" entered in the protocol registration and results system (prs) record.

Eligibility criteria:
no eligibility criteria
breast cancer, fitness and exercise for heart health: the be-fitter study

Conditions: Breast Cancer; Disability Physical; Heart Failure; Cardiotoxicity

Summary: the chemotherapy medications used for breast cancer treatment are important for achieving a cure, but a potential side effect is that they can cause a decline in functional capacity (reduced exercise tolerance and impaired physical function) and increase the risk of cardiovascular disease. the risks of decreased functional capacity and cardiovascular disease are highest in breast cancer survivors as they grow older. the factors causing the decline in functional capacity are not well understood, however they may be related to a reduction in cardiac function (e.g. decreased pumping ability of the heart) or skeletal muscle function (reduced muscle blood flow and oxygenation). exercise training is used for other populations at risk for cardiovascular disease (such as cardiac rehabilitation), but is not routinely offered to breast cancer survivors. therefore this research study wants to test whether exercise training can improve heart and muscle health, and increase functional capacity in up to 60 older breast cancer survivors aged \>60 years old who previously received chemotherapy drugs that can affect the heart. the purpose of this study is to compare two rehabilitation approaches: a 12-week structured exercise training program or a 12-week stretching-yoga program. the investigators want to compare whether these programs can improve functional capacity, and heart and skeletal muscle function. to do this, some of the participants in this study will be randomly enrolled in the structured exercise training program and others will be randomly enrolled in the stretching-yoga program.


Eligibility criteria:
inclusion criteria: * age ≥60 years * previously diagnosed with early-stage (i-iii) bc * completed (≥1 year post) primary cardiotoxic treatment (anthracycline-based chemotherapy or trastuzumab-based biological therapy). exclusion criteria: * have a history of coronary artery disease, heart failure, persistent and permanent arrhythmia (e.g. currently in atrial fibrillation), stroke, or chronic obstructive pulmonary disease * develop signs or symptoms of myocardial ischemia (≥1mm horizontal or down-sloping st segment depression on electrocardiogram) during the cardiopulmonary (vo2peak) test * have any research mri contraindications (e.g. any type of pacemaker), or any orthopedic limitation preventing exercise testing * currently performing structured exercise training (defined as ≥30 mins/day of moderate-to-vigorous aerobic and/or resistance exercise training on ≥4 days/week) * are unwilling to be randomized to either ext or stretch

Keywords: exercise training fitness heart muscle cancer survivorship
temocillin use in complicated urinary tract infections due to extended spectrum beta-lactamases (esbl)/ampc enterobacteriaceae

Conditions: Urinary Tract Infection

Summary: this study is aimed at demonstrating the efficacy of temocillin in the treatment of complicated urinary tract infection (uti) due to confirmed extended spectrum beta-lactamases (esbl) producing or ampc hyperproducing enterobacteriaceae in the united kingdom.

the spectrum of activity together with the route of excretion of temocillin makes it a good candidate for the treatment of urinary tract infections. several studies have shown very good clinical and microbiological activity in uncomplicated and complicated cystitis and pyelonephritis in adults and in pyelonephritis in children older than 2 months. however there is no specific study performed on urinary tract infections due to broad spectrum ß-lactamases producing strains. in this context, this study is aimed at demonstrating the efficacy of temocillin in the treatment of complicated urinary tract infection due to confirmed extended spectrum beta-lactamases (esbl) producing or ampc hyperproducing enterobacteriaceae in the united kingdom. the investigators will also evaluate the tolerance of the drug by monitoring the adverse event and the incidence of eventual clostridium difficile associated infection.

Eligibility criteria:
inclusion criteria: * patients presenting a complicated urinary tract infection due to a confirmed extended spectrum beta-lactamases (esbl) producing or ampc hyperproducing enterobacteriaceae susceptible to temocillin requiring parenteral antimicrobial therapy. * community or hospital acquired infecting bacteria. * signed informed consent exclusion criteria: * patients infected with a strain resistant to temocillin * patients having received an active antimicrobial therapy during the 48h before the beginning of temocillin treatment except temocillin * patients presenting another site of infection than urinary (except onset of bacteremia from urinary tract origin) due to gram negative bacteria * patients needing concomitant antimicrobial therapy with the exception of benzylpenicillin * uncomplicated cystitis * complete obstruction of the urinary tract * prostatitis * peri-nephretic or intrarenal abscesses * renal transplant * children (up to 18 years old) * pregnancy or lactation * chronically dialyzed patients * immunocompromising therapy or illness * known allergy to penicillin

Keywords: uti esbl ampc enterobacteriaceae
topical therapy for prevention of infections in preterm infants

Conditions: Skin Diseases

Summary: the purpose of this study is to determine how to best take care of the skin of preterm infants in order to prevent infections through the skin.

the skin of babies who are born too early is not mature, which means they are at risk for infections of the skin or in the body. their skin also become very dry, leading to cracking and breakdown, and this may feel painful or uncomfortable for the infant.

Eligibility criteria:
inclusion criteria: * preterm infants exclusion criteria: * full-term infant

Keywords: pre-term infants skin infections infant skin aquaphor sunflower seed oil nutrition skin care